Cartun R W, Coles F B, Pastuszak W T
Department of Pathology, Hartford Hospital, Connecticut 06115-0729.
Am J Pathol. 1987 Dec;129(3):415-21.
Immunophenotypic analysis of paraffin-embedded tissues of lymphoproliferative disorders has been facilitated by recent developments of monoclonal antibodies that react with epitopes that survive histologic processing. Leukocyte common antigen (LCA) antibody has made a significant contribution to the immunocytochemical separation of non-Hodgkin's lymphomas from nonlymphoid neoplasms. However, a small percentage of lymphomas, particularly some large cell or immunoblastic B-cell tumors, will not label with LCA antibody. Other antibodies, directed against B lymphocytes, experience problems of specificity and a lack of sensitivity when applied to formalin-fixed specimens. The authors recently investigated a monoclonal antibody (L26) that demonstrates excellent specificity and sensitivity for B lymphocytes, and tumors derived from them, in formalin- and B5-fixed, paraffin-embedded tissue. The avidin-biotin peroxidase complex (ABC) technique was utilized for immunostaining 95 cases of malignant lymphoproliferative disorders and a variety of normal and neoplastic nonlymphoid tissues. When applied to sections of benign lymphoid tissue, the L26 antibody labeled germinal center cells, mantle zone and scattered interfollicular lymphocytes, but not histiocytes or plasma cells. L26 marked 100% (44/44) of the large cell and immunoblastic B-cell lymphomas, along with 1 case of pre-B cell lymphoblastic lymphoma. This included 8 cases that were LCA-negative. None of the T-cell lymphomas or plasma cell tumors studied demonstrated L26 immunostaining. No normal, benign, or neoplastic nonlymphoid tissues examined stained with this antibody. L26 successfully labels B lymphocytes and B-cell lymphomas in routinely processed tissues, often with greater sensitivity and intensity than LCA. This antibody should prove invaluable in the investigation of atypical lymphoid proliferations and the identification of B-cell derived lymphomas, when fresh or frozen tissue is unavailable for analysis.
与经组织学处理后仍存活的表位发生反应的单克隆抗体的最新进展，推动了对石蜡包埋的淋巴增殖性疾病组织进行免疫表型分析。白细胞共同抗原（LCA）抗体对非霍奇金淋巴瘤与非淋巴样肿瘤的免疫细胞化学鉴别起到了重要作用。然而，一小部分淋巴瘤，特别是一些大细胞或免疫母细胞性B细胞肿瘤，不会被LCA抗体标记。其他针对B淋巴细胞的抗体，应用于福尔马林固定标本时存在特异性问题和缺乏敏感性的情况。作者最近研究了一种单克隆抗体（L26），该抗体在福尔马林和B5固定、石蜡包埋的组织中，对B淋巴细胞及其衍生的肿瘤显示出优异的特异性和敏感性。采用抗生物素蛋白-生物素过氧化物酶复合物（ABC）技术对95例恶性淋巴增殖性疾病以及各种正常和肿瘤性非淋巴样组织进行免疫染色。将L26抗体应用于良性淋巴组织切片时，可标记生发中心细胞、套区和散在的滤泡间淋巴细胞，但不标记组织细胞或浆细胞。L26标记了100%（44/44）的大细胞和免疫母细胞性B细胞淋巴瘤，以及1例前B细胞淋巴母细胞淋巴瘤。这其中包括8例LCA阴性的病例。所研究的T细胞淋巴瘤或浆细胞瘤均未显示L26免疫染色。所检查的正常、良性或肿瘤性非淋巴样组织均未被该抗体染色。L26能成功标记常规处理组织中的B淋巴细胞和B细胞淋巴瘤，其敏感性和强度通常高于LCA。当无法获得新鲜或冷冻组织进行分析时，该抗体在非典型淋巴样增殖的研究以及B细胞源性淋巴瘤的鉴别中应具有重要价值。
